In hepatic impairment, what is a common strategy for adjusting dosing?

• A. Reduce the dose or extend the dosing interval based on predicted decrease in hepatic clearance; guidelines or models needed.
• B. Increase the dose.
• C. No adjustment; hepatic impairment does not affect dosing.
• D. Switch to a non-hepatic elimination drug.

Answer: (A)

When the liver’s ability to metabolize and clear drugs is reduced, systemic exposure to drugs that are mainly eliminated by the liver tends to increase if dosing stays the same. A common way to address this is to either lower the dose or extend the dosing interval, with the goal of keeping exposure (AUC) similar to that seen in people with normal hepatic function. The exact adjustment is guided by predicted changes in hepatic clearance using clinical guidelines or modeling tools (for example, scoring systems like Child-Pugh or other PK models). This approach helps prevent toxicity while maintaining effectiveness. Increasing the dose would raise exposure in the setting of diminished clearance, and not adjusting ignores the impairment; switching to a non-hepatic elimination drug can be considered in some cases, but the standard, widely used strategy is dose reduction or interval extension based on predicted hepatic clearance decrease.